PharMetrics Inc.
This article was originally published in Start Up
Executive Summary
Over the years, the impact of patient behavior on drug revenues has grown with the increased focus on treatments for chronic ccnditions. To address this more patient-driven marketplace, PharMetrics Inc. has created a set of data and software tools designed to enhance the ability of pharmaceutical companies to better understand the patients currently using their products.
You may also be interested in...
Moving Beyond Market Share
Drug companies measure product success with market share--a measure appropriate to the one-time purchase of consumer goods, or even acute care drugs, but one that is increasingly irrelevant and, more important, misleading, for chronic care medicines. Market share largely measures new scrips and thus 80% of companies' promotional spending is aimed at convincing doctors to prescribe a drug--though in fact 80% of the economic value of a drug (and a similar percentage of its medical value) depends on patient behavior, in particularly getting and taking refills, which companies largely ignore. Companies need to adopt very different marketing strategies--and to start by measuring success differently, through metrics like persistence and intensity of product use.
AureoGen Biosciences Inc.
Formed by Kalamazoo-based Pharmacia alumni, AureoGen Biosciences Inc. is genetically engineering cyclic peptides to create second-generation, resistance-proof anti-infective and anti-fungal therapeutics.
Pain Therapeutics
Pain seems as close to a sure bet as the pharmaceutical industry has to offer. Forecasts call for the worldwide analgesic market, already $38 billion in 2002, to grow at a 20% annual clip, nearly doubling to $75 billion by the year 2010. For new drug developers, pain also has the advantage of offering clearly definable endpoints-less pain-and a relatively short duration for clinical trials. No surprise then that more than 200 companies have a hand in developing or marketing pain therapeutics. Among them, the three young companies profiled here-AlgoRx Pharmaceuticals Inc., Algos Therapeutics Inc., and TheraQuest Biosciences LLC.